Results 131 to 140 of about 98,500 (300)
Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy
BMEMat, EarlyView.Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu +5 more
wiley +1 more source
Estimated pulse wave velocity as a potential predictor of albuminuria in hypertension
Frontiers in MedicineBackgroundIncreased arterial stiffness is an important marker of target organ damage in hypertension. Estimated pulse wave velocity (ePWV) is a noninvasive assessment of arterial stiffness based on blood pressure and age calculations, but its association
Xianghui Zeng +5 more
doaj +1 more source
Voclosporin‐induced gingival enlargement: A case report
Clinical Advances in Periodontics, EarlyView.Abstract Background Drug‐influenced gingival enlargement (DIGE) is a recognized adverse effect of certain medications, particularly immunosuppressants like cyclosporin and tacrolimus. However, there have been no documented cases of DIGE associated with voclosporin, a newer calcineurin inhibitor used primarily to treat lupus nephritis.
Francesca Racca +2 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin +6 more
wiley +1 more source
Egyptian Pediatric Association GazetteBackground Chronic kidney disease is associated with several complications with higher prevalence and intensity at lower glomerular filtration rate. Albuminuria is the traditional biomarker of kidney damage.
Nourhan Essam Aboumosalam +3 more
doaj +1 more source
Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis
Clinical Pharmacology &Therapeutics, EarlyView.In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE.
Joachim Almquist +6 more
wiley +1 more source
Urinary Peptide Levels in Patients with Chronic Renal Failure [PDF]
, 2010 Introduction: Peptide levels in urine are found to be decreased in renal failure. In the current study urinary peptide levels were determined in chronic renal failure (CRF) patients.
M, Supriya +3 more
core
Streptozotocin induced hyperglycemia in the axolotl
Developmental Dynamics, EarlyView.Abstract Background Diabetes is a group of diseases characterized by loss of β cell mass and/or function, resulting in hyperglycemia. With no established curative treatment, this has initiated research in β cell regeneration. Current animal models have either limited regenerative capacity (mice) or small size and evolutionary distance from humans ...
Pernille Lajer Sørensen +2 more
wiley +1 more source
Role of selenium in the pathophysiology of cardiorenal anaemia syndrome
ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai +2 more
wiley +1 more source